Sunday 11 October 2026

One To Watch

Edesa Biotech

Canada's Edesa Biotech is focused on developing innovative treatments for underserved indications.

The biotech company has several products  in development that target dermatological and gastrointestinal disorders.

In June 2016, Edesa licensed the rights to ASF-1096 for use in anorectal disorders from Cipher Pharmaceuticals. ASF-1096 is a Phase II candidate that Cipher is investigating as a treatment for selected inflammatory skin disorders.

Want to Update your Company's Profile?


Latest Edesa Biotech News

Edesa Biotech prices $25 million public offering
21 August 2026
Cipher Pharma out-licenses rights to ASF-1096 to Edesa Biotech
22 June 2016
More Edesa Biotech news >


Today's issue

The week in pharma: action, reaction and insight – week to October 9, 2026
Biotechnology
The week in pharma: action, reaction and insight – week to October 9, 2026
10 October 2026
Pharmaceutical
Mineralys presents new data for lorundrostat
9 October 2026
Pharmaceutical
Colombian pharma groups sign alliance to fight counterfeit medicines
9 October 2026
Biotechnology
Outlook Therapeutics appoints Greg DiPasquale as CCO
9 October 2026
Biotechnology
Lonza and Onava collaborate to speed AI-native biologics discovery
9 October 2026
Pharmaceutical
FDA approves Teva’s Weltruza for schizophrenia
9 October 2026
Pharmaceutical
Foundayo potential as differentiated oral option for weight and glycemic control
9 October 2026




Copyright © The Pharma Letter 2026

 |  Headless Content Management with Blaze